Asymmetric Dimethylarginine Level in Children Undergoing Bone Marrow Transplantation

Ahmad, Dina Maher and Elhawary, Eslam E. and Fathy, Gamal Alden and Nagy, Hala Mohamed and Bedraya, Ibrahim Mohamed and Elshanshory, Mohamed Ramadan (2022) Asymmetric Dimethylarginine Level in Children Undergoing Bone Marrow Transplantation. Journal of Advances in Medicine and Medical Research, 34 (19). pp. 10-14. ISSN 2456-8899

[thumbnail of 4524-Article Text-8593-1-10-20220930.pdf]

Text
4524-Article Text-8593-1-10-20220930.pdf - Published Version
Download (440kB)

Official URL: https://doi.org/10.9734/jammr/2022/v34i1931430

Abstract

Background: Asymmetric dimethylarginine (ADMA) is a toxic, non‐proteinogenic amino acids formed by post‐translational modification and is a uremic toxin that inhibits nitric oxide (NO) production. The aim of this work was to assess the serum level of asymmetric dimethylarginine in children underwent bone marrow transplantation.

Methods: This prospective, randomized controlled study has been conducted on 20 children aged 2-18 years underwent bone marrow transplantation (Group I) and 20 healthy control children of matched age and sex (group II).

Results: The serum level of ADMA was significantly higher after bone marrow transplantation (p value <0.05).

Conclusions: Elevated ADMA level after bone marrow transplantation indicates that endothelial dysfunction is a main complication in those patients.

Item Type:	Article
Subjects:	Science Repository > Medical Science
Depositing User:	Managing Editor
Date Deposited:	05 Dec 2022 08:05
Last Modified:	02 Jun 2024 06:37
URI:	http://research.manuscritpub.com/id/eprint/692

Actions (login required)

: View Item